[Combined therapy of ovarian cancer (author's transl].
Following the introduction of massive triple drug therapy with high doses of Endoxan, Proresid and Methotrexat instead of the earlier long-term Endoxan treatment in addition of surgery, percutaneous irradiation and intraperitoneal radio-gold, 3 year survival of advanced stages IIb-IV of ovarian carcinoma rose from 19.6% to 42.6%. The 3 year survival of all malignant ovarian tumors (primary or secondary) rose from 38.3% to 51.0%. Further development led to targeted multiple drug therapy (ultrahigh Endoxan, Proresid/VM26, Methotrexat and Adriblastin) according to oncobiogram. The main side-effects, their control and experience with combined chemotherapy and irradiation are described.
D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006050:Gold Radioisotopes; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008517:Phytotherapy; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011035:Podophyllum / Q000627:therapeutic use
D006050:Gold Radioisotopes; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate
Die kombinierte Therapie des Ovarialkarzinoms